Filed for bankruptcy in Feb 2024
ARAV - Aravive, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Houston,
United States
Type: Equity
ARAV price evolution
ARAV
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10.94 | $20.75 | $38.38 | $56.13 |
| Short term investments | ||||
| Net receivables | $0.09 | |||
| Inventory | ||||
| Total current assets | $9.56 | $22.05 | $39.06 | $57.97 |
| Long term investments | ||||
| Property, plant & equipment | $1.07 | $1.3 | $1.52 | $1.73 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.49 | $3.69 | $3.98 | $4.18 |
| Total investments | ||||
| Total assets | $13.05 | $25.74 | $43.04 | $62.15 |
| Current liabilities | ||||
| Accounts payable | $5.42 | $3.89 | $9.79 | $8.77 |
| Deferred revenue | $2.65 | $3.61 | $5.04 | |
| Short long term debt | $2.12 | $2.15 | $2.17 | $2.19 |
| Total current liabilities | $9.78 | $14.22 | $20.19 | $22.11 |
| Long term debt | $0.31 | $0.82 | $1.35 | $1.88 |
| Total noncurrent liabilities | $1.57 | $31.33 | $61.46 | $29.38 |
| Total debt | $2.43 | $2.97 | $3.52 | $4.08 |
| Total liabilities | $11.35 | $45.55 | $81.66 | $51.5 |
| Shareholders' equity | ||||
| Retained earnings | -$626.85 | -$648.08 | -$666.08 | -$616.13 |
| Other shareholder equity | ||||
| Total shareholder equity | $1.7 | -$19.82 | -$38.61 | $10.66 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $56.13 | $61.85 | $62.97 | $67.56 |
| Short term investments | ||||
| Net receivables | $0.09 | $0.03 | $0.3 | $2.5 |
| Inventory | ||||
| Total current assets | $57.97 | $62.74 | $61.69 | $68.21 |
| Long term investments | ||||
| Property, plant & equipment | $1.73 | $2.61 | $3.48 | $10.51 |
| Goodwill & intangible assets | $0.1 | $0.22 | ||
| Total noncurrent assets | $4.18 | $5.04 | $6.02 | $13.91 |
| Total investments | ||||
| Total assets | $62.15 | $67.79 | $67.71 | $82.12 |
| Current liabilities | ||||
| Accounts payable | $8.77 | $2.66 | $2.5 | $1.08 |
| Deferred revenue | $5.04 | $8.12 | $6.32 | |
| Short long term debt | $2.19 | $2.3 | $2.09 | $2.39 |
| Total current liabilities | $22.11 | $17.94 | $9.46 | $4.97 |
| Long term debt | $1.88 | $4.08 | $6.43 | $7.84 |
| Total noncurrent liabilities | $29.38 | $7.62 | $10.19 | $8.1 |
| Total debt | $4.08 | $6.37 | $8.52 | $10.23 |
| Total liabilities | $51.5 | $25.57 | $19.66 | $13.07 |
| Shareholders' equity | ||||
| Retained earnings | -$616.13 | -$539.8 | -$500.65 | -$470.11 |
| Other shareholder equity | ||||
| Total shareholder equity | $10.66 | $42.22 | $48.05 | $69.05 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.76 | $1.27 | $1.49 | $1.47 |
| Cost of revenue | ||||
| Gross Profit | $2.76 | $1.27 | $1.49 | $1.47 |
| Operating activities | ||||
| Research & development | $8.73 | $10.79 | $15.91 | $17.95 |
| Selling, general & administrative | $2.94 | $3.07 | $3.49 | $3.38 |
| Total operating expenses | $11.67 | $13.86 | $19.4 | $21.34 |
| Operating income | -$8.91 | -$12.59 | -$17.91 | -$19.86 |
| Income from continuing operations | ||||
| EBIT | $21.23 | $18.01 | -$49.96 | -$29.13 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | $21.23 | $18.01 | -$49.96 | -$29.13 |
| Income (for common shares) | $21.23 | $18.01 | -$49.96 | -$29.13 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.14 | $7.44 | $5.68 | $4.75 |
| Cost of revenue | ||||
| Gross Profit | $9.14 | $7.44 | $5.68 | $4.75 |
| Operating activities | ||||
| Research & development | $66.94 | $37.54 | $17.62 | $12.84 |
| Selling, general & administrative | $13.04 | $10.55 | $13.06 | $13.69 |
| Total operating expenses | $79.97 | $48.09 | $36.47 | $26.53 |
| Operating income | -$70.84 | -$40.65 | -$30.78 | -$21.77 |
| Income from continuing operations | ||||
| EBIT | -$76.32 | -$39.15 | -$30.54 | -$18.22 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$76.32 | -$39.15 | -$30.54 | -$18.22 |
| Income (for common shares) | -$76.32 | -$39.15 | -$30.54 | -$18.22 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Net income | $21.23 | $18.01 | -$49.96 | -$29.13 |
| Operating activities | ||||
| Depreciation | $0.22 | $0.22 | $0.21 | $0.22 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.29 | $0.76 | $0.69 | $0.58 |
| Total cash flows from operations | -$9.81 | -$17.66 | -$17.75 | -$14.24 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $40.05 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.03 | $40.05 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.81 | -$17.63 | -$17.75 | $25.8 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$76.32 | -$39.15 | -$30.54 | -$18.22 |
| Operating activities | ||||
| Depreciation | $0.89 | $0.97 | $1.83 | $0.5 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.56 | $2.26 | $1.97 | $3.4 |
| Total cash flows from operations | -$65.08 | -$32.18 | -$12.17 | -$17.08 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | |||
| Investments | ||||
| Total cash flows from investing | -$0.01 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $59.37 | $31.06 | $7.58 | $25.25 |
| Net borrowings | ||||
| Total cash flows from financing | $59.37 | $31.06 | $7.58 | $25.25 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5.72 | -$1.12 | -$4.59 | $8.17 |
News
Fundamentals
| Market cap | $2.95M |
|---|---|
| Enterprise value | -$5.56M |
| Shares outstanding | 73.60M |
| Revenue | $7.00M |
|---|---|
| EBITDA | -$38.97M |
| EBIT | -$39.85M |
| Net Income | -$39.85M |
| Revenue Q/Q | -44.39% |
| Revenue Y/Y | -19.11% |
| P/E ratio | -0.07 |
|---|---|
| EV/Sales | -0.80 |
| EV/EBITDA | 0.14 |
| EV/EBIT | 0.14 |
| P/S ratio | 0.42 |
| P/B ratio | 1.74 |
| Book/Share | 0.02 |
| Cash/Share | 0.15 |
| EPS | -$0.54 |
|---|---|
| ROA | -110.70% |
| ROE | 345.97% |
| Debt/Equity | 4.83 |
|---|---|
| Net debt/EBITDA | -0.01 |
| Current ratio | 0.98 |
| Quick ratio | 0.98 |